Angiopoietin-2

Healio spoke with Rishi P. Singh, MD, about dual-targeting therapies in diabetic macular edema.

SAN FRANCISCO — Faricimab demonstrated sustained inhibition of both angiopoietin-2 and VEGF-A in patients with neovascular age-related macular degeneration, according to a presentation at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting.

Patient enrollment is complete in two phase 3 clinical trials investigating faricimab in diabetic macular edema, according to correspondence from Genentech and Roche.